Search results for " DIP"

showing 10 items of 1273 documents

Does sympathetic overactivation feature all hypertensives? Differences of sympathovagal balance according to night/day blood pressure ratio in patien…

2015

When evaluating the 'night/day BP ratio', both hypertensives and normotensives can be arbitrarily classified into four groups: extreme dippers (ratio ⩽0.8), dippers (0.8<ratio ⩽0.9), mild dippers (0.9<ratio⩽1.0) and reverse dippers (ratio ⩾1.0). Reverse and mild dipper hypertensives have poorer prognoses compared with the physiological dipper profile, but the prognostic relevance of the extreme dipper profile remains uncertain. The evaluation of heart rate variability (HRV), obtained by 24-h Holter ECG monitoring, is the most frequently used noninvasive form of assessment of the activity of the autonomic nervous system. Reverse and mild dipper hypertensives have reduced HRV, indicating an o…

MaleSympathetic nervous systemmedicine.medical_specialtySympathetic Nervous SystemSettore MED/09 - Medicina InternaAmbulatory blood pressurePhysiologyBlood Pressure030204 cardiovascular system & hematologyEssential hypertensionEssential hypertension03 medical and health sciences0302 clinical medicineHeart RateInternal medicineInternal MedicinemedicineHumansHeart rate variability030212 general & internal medicineHeart rate variabilityAgedbiologybusiness.industryDipperDiurnal/nocturnal blood pressure ratioBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseasebiology.organism_classificationCircadian RhythmAutonomic nervous systemmedicine.anatomical_structureBlood pressureQuartileHypertensionCardiologyFemaleExtreme dipperAmbulatory blood pressure monitoringCardiology and Cardiovascular MedicinebusinessHypertension Research
researchProduct

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

2014

Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti–complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether such abnormality occurs also in unaffected mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating complement profile (low C3, high C5a, or SC5b-9) was found in 47% to 64% of patients, irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular endotheli…

MaleTime FactorsClinical Trials and ObservationsComplement Membrane Attack Complexurologic and male genital diseasesBiochemistryGlomerulonephritisInside BLOOD Commentaryhemic and lymphatic diseasesMembranoproliferative glomerulonephritisMonoclonalHumanizedComplement ActivationAtypical Hemolytic Uremic SyndromeEndothelial CellHematologyRemission Inductionfood and beveragesHematologyComplement C3Eculizumabmedicine.anatomical_structureFactor HFemalecomplementaHUS eculizumabmedicine.drugMembranoproliferativeHumanmedicine.medical_specialtyEndotheliumMonitoringTime FactorGlomerulonephritis MembranoproliferativeImmunologyBiologyAntibodies Monoclonal HumanizedAntibodiesInternal medicineAtypical hemolytic uremic syndromemedicineHumansPhysiologicMonitoring PhysiologicAdenosine Diphosphate RiboseEndothelial CellsCell Biologymedicine.diseaseComplement systemImmunologyAdenosine Diphosphate Ribose; Antibodies Monoclonal Humanized; Atypical Hemolytic Uremic Syndrome; Complement Activation; Complement C3; Complement Membrane Attack Complex; Endothelial Cells; Female; Glomerulonephritis Membranoproliferative; Hemolytic-Uremic Syndrome; Humans; Male; Remission Induction; Time Factors; Monitoring Physiologic; Hematology; Biochemistry; Cell Biology; ImmunologyHemolytic-Uremic SyndromeComplement membrane attack complexBlood
researchProduct

Formation of mono- and diglucuronides and other glycosides of benzo(a)pyrene-3,6-quinol by V79 cell-expressed human phenol UDP-glucuronosyltransferas…

1995

Glucuronidation of quinols of polycyclic aromatic hydrocarbons (PAHs) represents an important detoxication pathway preventing toxic quinone/quinol redox cycles. Therefore, mono- and diglucuronide formation of benzo(a)pyrene-3,6-quinol was investigated and compared to that of structurally related 3,6-dihydroxychrysene and simple phenols (1-naphthol and 4-methylumbelliferone) using V79 cell-expressed human UGT1.6 (= P1) and human UGT1.7 (= P4). Properties of human UGT1.6 were compared to those of the rat ortholog. Cofactors related to UDP-glucuronic acid such as UDP-galacturonic acid and UDP-glucose were also studied. It was found that rat and human UGT1.6 and human UGT1.7 catalyse monoglucur…

MaleUridine Diphosphate GlucoseGlucuronosyltransferaseStereochemistryGlucuronidationGlucuronatesmacromolecular substancesBiochemistryIsozymeSubstrate Specificitychemistry.chemical_compoundGlucosidesAnimalsHumansPhenolsBenzopyrenesGlucuronosyltransferaseRats WistarCarcinogenPharmacologychemistry.chemical_classificationbiologyGlycosideHydroquinonesRatsQuinonechemistryBenzo(a)pyreneBiochemistryUridine Diphosphate Glucuronic Acidbiology.proteinBiochemical Pharmacology
researchProduct

A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with va…

1991

An open clinical trial was carried out to compare the efficacy and the tolerability of 1 g/day α-glycerylphosphorylcholine (α-GPC) with 1 g/day cytosine diphosphocholine (CDP) both given intramuscularly for 90 days in 120 patients with mild to moderate vascular dementia. The clinical evaluation, carried out at the start as well as halfway through (45 days) and at the end of treatment (90 days), was expressed by psychometric tests (modified Parkside behaviour rating scale, Sandoz clinical assessment geriatric scale, word fluency test, Hamilton's rating scale of depression, narration subtest of Wechsler memory scale). Both treatments produced a definite symptomatic improvement and showed a v…

MaleWechsler Memory Scalemedicine.medical_specialtyCytidine Diphosphate Cholinemedicine.medical_treatment030204 cardiovascular system & hematologyBiochemistrylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialRating scalelawInternal medicinemedicineDementiaHumansVascular dementiaAgedAged 80 and overPsychiatric Status Rating ScalesChemotherapybusiness.industryDementia VascularBiochemistry (medical)Cell BiologyGeneral MedicineDrug ToleranceMiddle Agedmedicine.diseaseGlycerylphosphorylcholineClinical trialTolerability030220 oncology & carcinogenesisAnesthesiaFemalebusinessThe Journal of international medical research
researchProduct

Peroxisome proliferator-activated receptor α (PPARα) activators induce hepatic farnesyl diphosphate synthase gene expression in rodents

2004

Fibrates are hypolipidemic drugs that exert multiple effects on lipid metabolism by activating peroxisome proliferator-activated receptor alpha (PPARalpha) and modulating the expression of many target genes. In order to investigate the link between PPARalpha and cholesterol synthesis, we analysed the effect of fibrates on expression of the farnesyl diphosphate synthase (FPP synthase) gene, known to be regulated by sterol regulatory element-binding proteins (SREBPs), in conjunction with HMG-CoA reductase. In wild-type mice, both fenofibrate and WY 14,643 induced FPP synthase gene expression, an effect impaired in PPARalpha-null mice. A three-fold induction was observed in ciprofibrate-treate…

Male[SDV]Life Sciences [q-bio]Endocrinology Diabetes and MetabolismClinical BiochemistryReceptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorCycloheximideBiochemistryGene Expression Regulation EnzymologicMice03 medical and health scienceschemistry.chemical_compoundEndocrinologyFarnesyl diphosphate synthaseGene expressionmedicineAnimalsReceptorMolecular BiologyComputingMilieux_MISCELLANEOUS030304 developmental biologyMice Knockoutchemistry.chemical_classification0303 health sciencesAlkyl and Aryl Transferasesbiology030302 biochemistry & molecular biologyGeranyltranstransferaseLipid metabolismCell BiologyPeroxisomeBlotting Northern3. Good healthCell biologyLiverchemistryBiochemistrybiology.proteinMolecular Medicinelipids (amino acids peptides and proteins)CiprofibrateTranscription Factorsmedicine.drugThe Journal of Steroid Biochemistry and Molecular Biology
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

Does single-event multilevel surgery enhance physical functioning in the real-life environment in children and adolescents with cerebral palsy (CP)?:…

2013

Orthopedic procedures are a method of treating gait deviations and musculoskeletal pathology that develop with age in cerebral palsy (CP). Recently single-event multilevel surgery (SEMLS) has become common practice. Although there is evidence that SEMLS could improve gait, it is unclear whether it will enhance overall physical functioning and coping strategies in the real-life environment. It is unclear how improved walking capacity affects actual functioning and enables greater independence. The aim of this study was to examine the perceptions of adolescents concerning the results of surgery on personal physical functioning in the environment five or more years after SEMLS. In this study, …

Malemedicine.medical_specialtyActivities of daily livingAdolescentmedicine.medical_treatmentBiophysicsCerebral palsySingle-event multilevel surgeryYoung AdultPhysical medicine and rehabilitationPatient satisfactionActivities of Daily LivingAgency (sociology)Spastic diplegiamedicineHumansOrthopedic ProceduresOrthopedics and Sports MedicineChildExerciseGaitExperienceRehabilitationRehabilitationta3141medicine.diseaseGaitSurgeryTreatment OutcomePatient SatisfactionGait analysisPhysical therapyCerebral palsyFemalePerceptionPsychologyPhysical functioningGait and Posture
researchProduct

Comparative study of the effects of chloral hydrate and trichloroethanol on cerebral metabolism

1973

The isolated perfused rat brain was used for a comparative study of the effects of chloral hydrate and trichloroethanol on cerebral energy metabolism. After a perfusion period of 30 min the brain levels of the following substrates and metabolites were measured spectrophotometrically: P-creatine, creatine, ATP, ADP, AMP, glycogen, glucose, glucose-6-P, fructose diphosphate, α-glycero-P, dihydroxyacetone-P, pyruvate, lactate, glutamate, α-ketoglutarate and ammonia. Furthermore, the concentration of chloral hydrate and trichloroethanol in the isolated brain and in the perfusion medium was measured colorimetrically. Little more than 10% of chloral hydrate in the isolated brain and in the perfus…

Malemedicine.medical_specialtyChloral hydrateIn Vitro TechniquesCreatinechemistry.chemical_compoundAdenosine TriphosphateInternal medicinemedicineAnimalsGlycolysisChloral HydrateBrain ChemistryPharmacologyEthanolEthanolGlycogenHydrocarbons HalogenatedBrainFructoseGeneral MedicineIsolated brainCreatineAdenosine MonophosphateRatsAdenosine DiphosphatePerfusionAdenosine diphosphateGlucoseEndocrinologyBiochemistrychemistryCattleChlorineGlycolysisGlycogenmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Immunity to diphtheria in the 3–19 year age group in Italy

1991

In Italy, immunization with diphtheria toxoid has been compulsory for all newborns since 1939. The last two clinical cases of diphtheria were reported in 1987. During the period 1987-1989, immunity against diphtheria was assessed by neutralization test in a random sample of 1740 healthy subjects 3-19 years old, from five geographical areas of Italy. Of the total population, 76.5% showed antibody levels considered to be protective (greater than or equal to 0.1 IU ml-1), 17.2% had a relative degree of protection (0.01-0.09 IU ml-1), and 6.3% lacked immunity (less than 0.01 IU ml-1). The percentage of unprotected subjects increased from 6.1% in the age group of 3-5 years to 11.4% in the age gr…

Malemedicine.medical_specialtyDiphtheria ToxoidBooster doseDisease OutbreaksNeutralization TestsImmunityEpidemiologyHumansMedicineChildDiphtheria toxinGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryCorynebacterium diphtheriaeIncidenceDiphtheriaIncidence (epidemiology)Public Health Environmental and Occupational HealthDiphtheriaOdds ratiomedicine.diseaseAntibodies BacterialConfidence intervalInfectious DiseasesItalyChild PreschoolImmunologyMolecular MedicineFemalebusinessDemographyVaccine
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct